848 related articles for article (PubMed ID: 17615153)
1. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
Periyasamy S; Warrier M; Tillekeratne MP; Shou W; Sanchez ER
Endocrinology; 2007 Oct; 148(10):4716-26. PubMed ID: 17615153
[TBL] [Abstract][Full Text] [Related]
2. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.
Periyasamy S; Hinds T; Shemshedini L; Shou W; Sanchez ER
Oncogene; 2010 Mar; 29(11):1691-701. PubMed ID: 20023700
[TBL] [Abstract][Full Text] [Related]
3. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506.
Davies TH; Ning YM; Sánchez ER
Biochemistry; 2005 Feb; 44(6):2030-8. PubMed ID: 15697228
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
5. The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.
Kawahara T; Kashiwagi E; Ide H; Li Y; Zheng Y; Ishiguro H; Miyamoto H
Prostate; 2015 May; 75(6):573-84. PubMed ID: 25631176
[TBL] [Abstract][Full Text] [Related]
6. Immunophilin-protein interactions in Plasmodium falciparum.
Leneghan D; Bell A
Parasitology; 2015 Sep; 142(11):1404-14. PubMed ID: 26156578
[TBL] [Abstract][Full Text] [Related]
7. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
8. FKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells.
Maeda K; Habara M; Kawaguchi M; Matsumoto H; Hanaki S; Masaki T; Sato Y; Matsuyama H; Kunieda K; Nakagawa H; Shimada M
Mol Oncol; 2022 Feb; 16(4):940-956. PubMed ID: 34057812
[TBL] [Abstract][Full Text] [Related]
9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
10. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
12. Effect of geldanamycin on androgen receptor function and stability.
Vanaja DK; Mitchell SH; Toft DO; Young CY
Cell Stress Chaperones; 2002 Jan; 7(1):55-64. PubMed ID: 11894840
[TBL] [Abstract][Full Text] [Related]
13. Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology.
Yong W; Yang Z; Periyasamy S; Chen H; Yucel S; Li W; Lin LY; Wolf IM; Cohn MJ; Baskin LS; Sa Nchez ER; Shou W
J Biol Chem; 2007 Feb; 282(7):5026-5036. PubMed ID: 17142810
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
15. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S
Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
18. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
Yeap BB; Krueger RG; Leedman PJ
Endocrinology; 1999 Jul; 140(7):3282-91. PubMed ID: 10385425
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
20. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP.
Zhu W; Zhang JS; Young CY
Carcinogenesis; 2001 Sep; 22(9):1399-403. PubMed ID: 11532861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
